BioCryst to buy Astria Therapeutics in $700 million deal

BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, as it looks to expand its portfolio of treatments for rare diseases. ...